- The OWS award funds large-scale manufacturing of NVX-CoV2373, Novavax's (NASDAQ:NVAX) COVID-19 vaccine candidate including production of 100M doses starting in late 2020.
- That includes a pivotal Phase 3 clinical trial with up to 30,000 subjects beginning in the fall of 2020. A Phase 1/2 clinical trial of NVX-CoV2373 in 130 healthy participants 18 to 59 years of age began in Australia in May.
- Preliminary immunogenicity and safety results are expected at the end of July, and the Phase 2 portion to assess immunity, safety, and COVID-19 disease reduction is expected to begin thereafter.
- NVAX +19.6% premarket